

Study Title	A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Protocol Number	IMGN853-416 MIRASOL
Sponsor	ImmunoGen, Inc.
Contact	Li Hoon Lai, Oncology Research Team Leader at lihoonlai@cabrini.com.au

Study Type	Study Phase	Recruitment Status	Lead Oncologist
<i>Treatment</i>	<i>Phase 3</i>	<i>Open</i>	<i>A/Prof Gary Richardson</i>

Participation Eligibility

Participant eligibility for a trial may include age, gender, type and stage of disease, and previous or current treatments and health complications. Every trial has specific inclusion and exclusion criteria and these may differ from trial to trial. The inclusion and exclusion guidelines identify who can and cannot participate in this trial. A brief explanation of this study including the inclusion and exclusion criteria is available at this public domain website

<https://www.clinicaltrials.gov/ct2/show/NCT04209855?term=imgn853+mirasol&draw=2&rank=1>

If you need assistance understanding the eligibility criteria, you or your doctor can contact the study team